A COMBINATION CHEMOENDOCRINE THERAPY OF MITOXANTRONE, DOXIFLURIDINE, AND MEDROXYPROGESTERONE ACETATE FOR ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER
Y. Iino et al., A COMBINATION CHEMOENDOCRINE THERAPY OF MITOXANTRONE, DOXIFLURIDINE, AND MEDROXYPROGESTERONE ACETATE FOR ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER, Cancer chemotherapy and pharmacology, 41(3), 1998, pp. 243-247
Between January 1993 and October 1995, 34 patients with anthracycline-
resistant advanced breast cancer were treated with a combination chemo
endocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and m
edroxyprogesterone acetate (MPA). Of 34 patients, 28 were evaluable fo
r efficacy of this combination therapy, and 30 including 2 for whom da
ta were incomplete were assessed for adverse drug reactions. Adriamyci
n (ADM) was used for pretreatment in 12 patients, 4'-epi-ADM in 6, and
THP-ADM in 12. In the eligible patients, 8.0 mg/m(2) MIT was administ
ered intravenously every 4 weeks, and 600 mg MPA and 600 mg 5'-DFUR we
re given orally every day. The median follow-up period was 25 weeks (r
ange 2-90 weeks). The median cumulative dose of mitoxantrone was 66 mg
(range 12-121 mg). Of the 28 patients, 11 (39.3%) responded to this c
ombination therapy. As for response in relation to predominant site of
lesion, 1 of 5 soft tissue lesions (20%) and 8 of 12 bone metastases
(66.7%) showed a partial response, and one complete response and one p
artial response (25.0%) were seen in eight lung lesions. None of three
pleural lesions responded to this therapy. The median duration of res
ponse was 31 +/- weeks (range 12-82 weeks). Adverse drug reactions wer
e controllable or tolerable. Combined chemoendocrine therapy with a lo
w dose of MIT is a well-tolerated and moderately effective regimen for
the treatment of anthracycline-resistant advanced breast cancer.